BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 14761917)

  • 1. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity.
    Sabel MS; Skitzki J; Stoolman L; Egilmez NK; Mathiowitz E; Bailey N; Chang WJ; Chang AE
    Ann Surg Oncol; 2004 Feb; 11(2):147-56. PubMed ID: 14761917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity.
    Arora A; Su G; Mathiowitz E; Reineke J; Chang AE; Sabel MS
    J Surg Oncol; 2006 Oct; 94(5):403-12. PubMed ID: 16967445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
    Sabel MS; Su G; Griffith KA; Chang AE
    Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres.
    Sabel MS; Arora A; Su G; Griffith KA; Mathiowitz E; Reineke JJ; Chang AE
    J Immunother; 2007; 30(8):808-16. PubMed ID: 18049332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.
    Egilmez NK; Jong YS; Sabel MS; Jacob JS; Mathiowitz E; Bankert RB
    Cancer Res; 2000 Jul; 60(14):3832-7. PubMed ID: 10919657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases.
    Sabel MS; Hill H; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Surgery; 2001 Sep; 130(3):470-8. PubMed ID: 11562672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes.
    Ahlers JD; Dunlop N; Alling DW; Nara PL; Berzofsky JA
    J Immunol; 1997 Apr; 158(8):3947-58. PubMed ID: 9103465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice.
    Lasek W; Feleszko W; Golab J; Stokłosa T; Marczak M; Dabrowska A; Malejczyk M; Jakóbisiak M
    Cancer Immunol Immunother; 1997 Oct; 45(2):100-8. PubMed ID: 9390201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
    Tähtinen S; Kaikkonen S; Merisalo-Soikkeli M; Grönberg-Vähä-Koskela S; Kanerva A; Parviainen S; Vähä-Koskela M; Hemminki A
    PLoS One; 2015; 10(6):e0131242. PubMed ID: 26107883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice.
    Lasek W; Mackiewicz A; Czajka A; Switaj T; Goł b J; Wiznerowicz M; Korczak-Kowalska G; Bakowiec-Iskra EZ; Gryska K; Izycki D; Jakóbisiak M
    Cancer Gene Ther; 2000 Dec; 7(12):1581-90. PubMed ID: 11228537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
    Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
    Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.
    Kuriakose MA; Chen FA; Egilmez NK; Jong YS; Mathiowitz E; DeLacure MD; Hicks WL; Loree TL; Bankert RB
    Head Neck; 2000 Jan; 22(1):57-63. PubMed ID: 10585606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.